Dudediligence.

Acadia Pharmaceuticals Inc

ACADNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$250.4MSep ’24$259.6MDec ’24$244.3MMar ’25$264.6MJun ’25$278.6MSep ’25$284.0MDec ’25$268.1MMar ’26$308.0MJun ’26
Net income, by quarter
$32.8MSep ’24$143.7MDec ’24$19.0MMar ’25$26.7MJun ’25$71.8MSep ’25$273.6MDec ’25$3.6MMar ’26$31.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$484.1M$517.2M$726.4M$957.8M$1.07B
Gross profit$465.0M$507.1M$684.8M$876.0M$982.5M
Operating income−$170.4M−$223.6M−$73.4M$230.8M$104.8M
Net income−$167.9M−$216.0M−$61.3M$226.5M$391.0M
Operating cash flow−$125.7M−$114.0M$16.7M$157.7M$109.8M
Free cash flow−$126.8M−$114.0M$16.7M$157.2M$105.1M
Cash$147.4M$114.8M$188.7M$319.6M$177.7M
Shares outstanding161.0M162.1M164.7M166.7M170.3M